Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism

Detalhes bibliográficos
Autor(a) principal: Cordeiro,Giovana Vignoli
Data de Publicação: 2013
Outros Autores: Silva,Ivani Novato, Goulart,Eugênio Marcos Andrade, Chagas,Antônio José das, Kater,Cláudio Elias
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005
Resumo: OBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were eva­luated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone.
id SBEM-2_f5861ae21fda11af53c5c692faeede54
oai_identifier_str oai:scielo:S0004-27302013000200005
network_acronym_str SBEM-2
network_name_str Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
repository_id_str
spelling Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenismCongenital adrenal hyperplasiasteroid 21-hydroxylasecorticosteroidshydrocortisonebody heightOBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were eva­luated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone.Sociedade Brasileira de Endocrinologia e Metabologia2013-03-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005Arquivos Brasileiros de Endocrinologia & Metabologia v.57 n.2 2013reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)instacron:SBEM10.1590/S0004-27302013000200005info:eu-repo/semantics/openAccessCordeiro,Giovana VignoliSilva,Ivani NovatoGoulart,Eugênio Marcos AndradeChagas,Antônio José dasKater,Cláudio Eliaseng2013-03-19T00:00:00Zoai:scielo:S0004-27302013000200005Revistahttps://www.aem-sbem.com/ONGhttps://old.scielo.br/oai/scielo-oai.php||abem-editoria@endocrino.org.br1677-94870004-2730opendoar:2013-03-19T00:00Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)false
dc.title.none.fl_str_mv Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
title Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
spellingShingle Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
Cordeiro,Giovana Vignoli
Congenital adrenal hyperplasia
steroid 21-hydroxylase
corticosteroids
hydrocortisone
body height
title_short Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
title_full Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
title_fullStr Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
title_full_unstemmed Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
title_sort Final height in congenital adrenal hyperplasia: the dilemma of hypercortisolism versus hyperandrogenism
author Cordeiro,Giovana Vignoli
author_facet Cordeiro,Giovana Vignoli
Silva,Ivani Novato
Goulart,Eugênio Marcos Andrade
Chagas,Antônio José das
Kater,Cláudio Elias
author_role author
author2 Silva,Ivani Novato
Goulart,Eugênio Marcos Andrade
Chagas,Antônio José das
Kater,Cláudio Elias
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Cordeiro,Giovana Vignoli
Silva,Ivani Novato
Goulart,Eugênio Marcos Andrade
Chagas,Antônio José das
Kater,Cláudio Elias
dc.subject.por.fl_str_mv Congenital adrenal hyperplasia
steroid 21-hydroxylase
corticosteroids
hydrocortisone
body height
topic Congenital adrenal hyperplasia
steroid 21-hydroxylase
corticosteroids
hydrocortisone
body height
description OBJECTIVE: The purpose of this study was to identify factors that might interfere with reaching the final height in patients with 21-hydroxylase deficiency (21-OHD). SUBJECTS AND METHODS: Thirty-one patients with classical 21-OHD who reached their FH in our Institution were eva­luated in order to compare the Z score for final height (FHZ) with: (1) the target height, (2) the standard height for the population, and (3) the hydrocortisone treatment schedule. RESULTS: The FHZ of -2.13 ± 1.11 had a significant negative correlation with the hydrocortisone doses used throughout the period of study. Patients who reached FH within the normal population range were those who received lower doses of hydrocortisone, as compared to those whose FH remained below -2 SDS. CONCLUSION: We conclude that careful treatment adjustments have a major influence on growth of children with CAH, and that the dose range for hydrocortisone replacement that does not lead to side effects is relatively narrow. The better height outcome was achieved in 21-OHD patients who received lower doses of hydrocortisone.
publishDate 2013
dc.date.none.fl_str_mv 2013-03-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-27302013000200005
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/S0004-27302013000200005
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
publisher.none.fl_str_mv Sociedade Brasileira de Endocrinologia e Metabologia
dc.source.none.fl_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia v.57 n.2 2013
reponame:Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
instname:Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron:SBEM
instname_str Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
instacron_str SBEM
institution SBEM
reponame_str Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
collection Arquivos Brasileiros de Endocrinologia & Metabologia (Online)
repository.name.fl_str_mv Arquivos Brasileiros de Endocrinologia & Metabologia (Online) - Sociedade Brasileira de Endocrinologia e Metabologia (SBEM)
repository.mail.fl_str_mv ||abem-editoria@endocrino.org.br
_version_ 1754734812233465856